ALL
-
-
Oct 02, 2019 product/service
-
-
product/service
-
Notice Regarding Approval of Partial Amendments to Dosage and Administration of Candesartan Tablets 2mg / 4mg / 8mg / 12mg “FFP” for KYOSOMIRAI PHARMA(158 KB)
-
-
Sep 02, 2019 product/service
-
-
product/service
-
Notice Regarding Launch of 1 Ingredient / 2 Products of Generic Drugs for KYOSOMIRAI PHARMA(47 KB)
-
-
Aug 16, 2019 stock
-
-
stock
-
Notice Regarding Completion of Payment Concerning Disposal of Treasury Stock as Restricted Stock Compensation(145 KB)
-
-
Aug 01, 2019 performance
-
-
performance
-
Summary of Consolidated Financial Results for the First Quarter of Fiscal Year Ending March 31, 2020(221 KB)
-
-
Jul 19, 2019 stock
-
-
stock
-
Notice Regarding Disposal of Treasury Stock as Restricted Stock Compensation(112 KB)
-
-
Jul 18, 2019 product/service
-
-
product/service
-
Notice Regarding Approval of Partial Amendments to Indications, Dosage and Administration of Donepezil Hydrochloride Tablets 3mg / 5mg / 10mg “FFP” and Donepezil Hydrochloride OD Tablets 3mg / 5mg / 10mg “FFP” for KYOSOMIRAI PHARMA(48 KB)
-
-
Jun 27, 2019 corporate
-
-
corporate
-
Notice Regarding Executive Appointment(62 KB)
-
-
Jun 27, 2019 corporate
-
-
corporate
-
Notice Regarding Change of Representative Directors(62 KB)
-
-
Jun 27, 2019 corporate
-
-
corporate
-
Notice Regarding Executive Appointment of a Subsidiary(65 KB)
-
-
Jun 27, 2019 corporate
-
-
corporate
-
Notice Regarding Change of Representative Directors of a subsidiary(59 KB)
-
-
Jun 14, 2019 product/service
-
-
product/service
-
Notice Regarding Launch of 1 Ingredient / 4 Products of Generic Drugs for KYOSOMIRAI PHARMA(65 KB)
-
-
May 09, 2019 stock
-
-
stock
-
Announcement about the Adjustment of the Conversion Value for Euro-Yen Denominated Convertible Bonds Maturing in 2019(12 KB)
-
-
May 09, 2019 performance
-
-
performance
-
Summary of Consolidated Financial Results of Fiscal Year Ended March 31, 2019(455 KB)
-
-
Apr 24, 2019 performance
-
-
performance
-
Notice Regarding Revision of the Full-year Earnings Forecasts for Fiscal Year Ended March 2019(21 KB)
